Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

prilosec

- PMLiVE

Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

- PMLiVE

AstraZeneca opens new global strategic R&D centre in US

The new centre will be home to nearly 2,000 world-class researchers and scientists

- PMLiVE

AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

- PMLiVE

Lilly gets FDA approval for severe alopecia areata treatment for paediatric patients

Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes

- PMLiVE

Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal

The deal focuses on addressing critical unmet medical needs

- PMLiVE

AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer

The results from a global phase 3 trial show the longest survival data ever reported in this setting

- PMLiVE

Lilly to acquire Merida Biosciences in deal worth up to $2.875bn

The acquisition is to advance treatments for serious autoimmune and allergic diseases

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

- PMLiVE

Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA

There are currently no approved human vaccines for Lyme disease

- PMLiVE

Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes

The UK is the first country in Europe to authorise the oral medication

- PMLiVE

NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia

The treatments are for eligible adults in England and Wales

- PMLiVE

Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer

Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links